HK$11.37 close for XtalPi 2228.HK on 11 Feb 2026: AI drug discovery outlook

The 2228.HK stock closed at HK$11.37 on 11 Feb 2026, up 0.08 or 0.71% for the session in Hong Kong (HKSE). Trading volume reached 43,290,767.00 shares, and the stock traded between HK$11.23 and HK$11.53 today. XtalPi Holdings Ltd (2228.HK) remains an AI-first drug discovery and automation company. We assess valuation, technical momentum, and near-term catalysts, and we link recent market moves to earnings and sector trends in Hong Kong healthtech.

2228.HK stock: price action and market context

XtalPi (2228.HK) finished the market session at HK$11.37 on 11 Feb 2026, a +0.71% daily change from the previous close of HK$11.29. The stock is +14.11% year-to-date and sits between its 50-day average HK$10.94 and 200-day average HK$8.93.

Volume today was 43,290,767.00 versus an average of 73,760,482.00, showing solid retail and institutional interest in Hong Kong. The stock’s year high is HK$15.12 and year low is HK$3.85, which frames recent gains.

Financials and valuation for 2228.HK stock

XtalPi reports an EPS of HK$1.05 and a reported PE of 10.86 on the HKSE quote, with market cap about HK$49,058,438,075.00. Key ratios show high revenue efficiency but mixed cash metrics, with book value per share HK$1.87 and cash per share HK$0.92.

Price-to-sales and EV multiples look rich versus peers, with price-to-sales near 63.66 and PB around 5.42, which implies growth expectations priced into the stock. Investors should weigh these ratios against AI-driven revenue potential.

Technicals and trading signals for 2228.HK stock

Technicals show strong momentum: RSI is 76.82 (overbought), MACD histogram is 0.35, and ADX is 30.64 indicating a strong trend. Bollinger upper band is HK$11.80, middle HK$9.99, lower HK$8.17.

Short-term indicators warn of a pullback risk. On-balance volume is negative at -355,382,607.00, while MFI is 79.67, suggesting heavy buying but potential exhaustion. Traders should watch support at HK$10.94 and resistance near HK$11.80.

Meyka AI grade and analyst consensus on 2228.HK stock

Meyka AI rates 2228.HK with a score of 63.17 out of 100 — Grade B, suggestion HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus.

Independent rating data dated 2026-02-10 shows a company score of C- from another provider, so market views vary. Use Meyka AI’s grade alongside other research when sizing positions in this healthcare AI stock.

Risks, catalysts, and sector context for 2228.HK stock

Key risks include long cash conversion cycles, negative operating cash flow per share HK$-0.11, and dependency on R&D outcomes. Price volatility is elevated given biotech and AI exposure.

Catalysts include upcoming earnings on 27 Mar 2026, new AI drug programme updates, and partnership announcements. The healthcare sector in Hong Kong shows mixed performance, so sector momentum will influence XtalPi’s trading.

Forecasts and price targets for 2228.HK stock

Meyka AI’s forecast model projects a monthly target of HK$14.10, quarterly target HK$13.43, and yearly target HK$10.47. These figures reflect scenario-based AI adoption and revenue growth assumptions.

Forecasts are model-based projections and not guarantees. The monthly target implies implied upside vs current price of +24.05% to HK$14.10, while the yearly projection implies downside of -7.91% to HK$10.47.

Final Thoughts

XtalPi Holdings Ltd (2228.HK) closed at HK$11.37 on 11 Feb 2026 with clear AI-driven momentum and mixed fundamentals. The stock shows strong technical momentum, with RSI 76.82 and ADX 30.64, which signals trend strength but also short-term overbought conditions. Valuation metrics are elevated: price-to-sales near 63.66 and PB around 5.42, which demand sustained growth to justify the multiple. Meyka AI’s forecast model projects a near-term monthly price of HK$14.10, implying +24.05% upside from today’s close. This forecast contrasts with a lower one-year projection of HK$10.47, implying a -7.91% downside if growth slows. Our view: active investors can consider sized exposure ahead of the 2026-03-27 earnings report, but risk-aware investors should wait for clearer revenue and cash flow improvements. Use Meyka AI’s tools and sector monitoring for updates, and review the company’s earnings and partnership announcements to adjust position sizing.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.